Application of tirofiban and thrombus-aspiration catheter in the percutaneous coronary intervention-treated patients with acute ST-segment elevation myocardial infarction

( views:260, downloads:0 )
Author:
WANG Guo-hua(Department of Cardiology, The Second People's Hospital of Hunan Province, Changsha 410005, China)
LIU Hui(Department of Cardiology, The Second People's Hospital of Hunan Province, Changsha 410005, China)
YUAN Li-li(Department of Cardiology, The Second People's Hospital of Hunan Province, Changsha 410005, China)
WU Chun-yuan(Department of Cardiology, The Second People's Hospital of Hunan Province, Changsha 410005, China)
Journal Title:
Journal of Chinese Physician
Issue:
Volume 14, Issue 09, 2012
DOI:
10.3760/cma.j.issn.1008-1372.2012.09.014
Key Word:
Tyrosine/analogs & derivatives/pharmacology;Suction;Myocardial infarction/therapy;Angioplasty, transluminal, percutaneous coronary

Abstract: Objective To assess the effects and safety of glycoprotein Ⅱ b/Ⅲ a receptor inhibitors tirofiban( intracoronary administration and venous maintenance) combined with DIVERTM CE thrombus-aspiration catheter in the percutaneous coronary intervention (PCI)-treated patients with acute ST-segment elevation myocardial infarction (ST-EMI).Methods Sixty patients with ST-EMI who underwent PCI were randomized into two groups.Thirty-two patients in group A were treated with tirofiban,twenty-eight patients in group B were treated with tirofiban and thrombus-aspiration catheter.Between two groups,the thrombolysis in myocardial infarction (TIMI) risk score,hemorrhagic complications,and incidence of major adverse cardiovascular events (MACE) were compared.Results The TIMI flow was improved in both groups,and it was better in group B than group A ( P < 0.05 ).The incidence of MACE in group B was lower than group A (25.0% vs 3.6%,P <0.05). No fatal hemorrhagic complications were found in both groups.Conclusions Application of tirofiban and DIVERTM CE thrombus-aspiration catheter is safe and effective in ST-EMI patients,which can greatly improve myocardial reperfusion and reduce incidence of MACE.

  • [1]Zhang Q,Zhang RY,Zhang JS,et al.Outcomes of primary percutaneous coronary intervention for acute ST-elevation myocardial infarction in patients aged over 75 years.Chin Med J (Ensl),2006,119(14):1151-1156.
  • [2]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志,2010,38(8):675-690.
  • [3]Valero SJ,Moreno R,Reyes RM,et al. Pharmacological approach of no-reflow phenomenon related with percutaneous coronary interventions. Cardiovasc Hematol Agents Med Chem,2008,6(2):125-129.
  • [4]陆再英,钟南山.内科学.7版.北京:人民卫生出版社,2008:300.
  • [5]Mihatov S.Thrombolysis or percutaneous coronary intervention in acute myocardial infarct.Acta Med Croatica,2004,58 (2):139-142.
  • [6]Resnic FS,WainsteinM,Lee MK,et al.No-reflow is an independ-entpredictor ofdeath and myocardial infarction after percutaneous coro-nary intervention.Am Heart J,2003,145 (1):42-46.
  • [7]Ikari Y,Sakurada M,Kozuma K,et al.Upfront thrombus aspiration in primary coronary intervention for patients with ST-segment elevation acute myocardial infarction:report of the VAMPIRE (VAcuuM asPIration thrombus REmoval) trial.JACC Cardiovasc Interv,2008,1 (4):424-431.
  • [8]Danzi GB,Capuano C,Sesana M,et al.Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein Ⅱ b/Ⅲ a receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.Am J Cardiol,2006,97(4):489-493.
  • [9]Zhu TQ,Zhang Q,Qiu JP,et al.Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention:The ICT-AMI study.Int J Cardiol,2011,20.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn